Y-mAbs starts rolling U.S. application for omburtamab for type of pediatric cancer

Y-mAbs Therapeutics (NASDAQ:YMAB) launches the rolling submission of its U.S. marketing application seeking approval of omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastases (cancer has spread to the membranes lining the brain and spinal cord) from neuroblastoma.

Omburtamab is a monoclonal antibody that binds to an immune checkpoint molecule called B7-H3 that is over-expressed in several types of cancer.

https://seekingalpha.com/news/3587526-y-mabs-commences-rolling-u-s-application-for-omburtamab-for-type-of-pediatric-cancer